Ad Scientiam facilitates access for patients with multiple sclerosis to MSCopilot®, faced with Covid-19

June 9, 2020

As lockdown measures begin to decrease in France, people with neurological or psychiatric diseases are still at risk from Covid-19.

To support these patients, Ad Scientiam - a startup located within the iPEPS incubator - The Healthtech Hub of the Brain Institute - is accelerating the distribution of MSCopilot®, the first CE marked medical device allowing the monitoring of patients with multiple sclerosis.

Share

MSCopilot®: New clinical results confirm central role of digital biomarkers in the monitoring of patients with multiple sclerosis Our news
en_USEnglish